Cellosaurus TC-71 (CVCL_2213)

Cell line name TC-71
Synonyms TC71; GM11654
Accession CVCL_2213
Resource Identification Initiative To cite this cell line use: TC-71 (RRID:CVCL_2213)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 15 hours (PubMed=20922763); 26 hours (PubMed=25984343); ~24 hours (DSMZ); 21 hours (COG).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Homozygous for a CDKN2A deletion (PubMed=18160777).
Sequence variation: TP53 p.Arg213Ter (PubMed=19787792).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Ewing sarcoma (NCIt: C4817)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_QW72 (TC-CD99-shRNA#1); CVCL_QW73 (TC-CD99-shRNA#2); CVCL_QW71 (TC-CTR-shRNA)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): COG; Cosmic-CLP; DSMZ; PubMed=20922763; PubMed=24312454; PubMed=25877200

Markers:
AmelogeninX,Y (Cosmic-CLP; COG; PubMed=20922763; PubMed=24312454)
X (DSMZ; PubMed=25877200)
CSF1PO10,11
D13S31711,12
D16S53911,14
D18S5112,15
D19S43314,16.2
D21S1129,30
D2S133820,24
D3S135815,17
D5S81810
D7S82010
D8S117910,12
FGA24,26
Penta D11,14
Penta E12
TH019.3
TPOX8,9
vWA17 (COG; DSMZ; PubMed=20922763; PubMed=24312454; PubMed=25877200)
17,19 (Cosmic-CLP)
Web pages http://www.cogcell.org/dl/EFT_Lines_DataSheets/TC-71_Cell_Line_Data_Sheet_COGcell_org.pdf
http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://tcpaportal.org/mclp/
Publications

PubMed=3004699; DOI=10.1016/0165-4608(86)90001-4
Whang-Peng J., Triche T.J., Knutsen T., Miser J., Kao-Shan S., Tsai S., Israel M.A.
Cytogenetic characterization of selected small round cell tumors of childhood.
Cancer Genet. Cytogenet. 21:185-208(1986)

PubMed=3390826
McKeon C., Thiele C.J., Ross R.A., Kwan M., Triche T.J., Miser J.S., Israel M.A.
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Cancer Res. 48:4307-4311(1988)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)

PubMed=18160777; DOI=10.1159/000109614
Savola S., Nardi F., Scotlandi K., Picci P., Knuutila S.
Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma.
Cytogenet. Genome Res. 119:21-26(2007)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=20197622; DOI=10.1172/JCI36667
Rocchi A., Manara M.C., Sciandra M., Zambelli D., Nardi F., Nicoletti G., Garofalo C., Meschini S., Astolfi A., Colombo M.P., Lessnick S.L., Picci P., Scotlandi K.
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
J. Clin. Invest. 120:668-680(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24312454; DOI=10.1371/journal.pone.0080060
May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L., Jenabi J., Ji L., Triche T.J., Lawlor E.R., Reynolds C.P.
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
PLoS ONE 8:E80060-E80060(2013)

PubMed=25010205; DOI=10.1371/journal.pgen.1004475
Brohl A.S., Solomon D.A., Chang W., Wang J., Song Y., Sindiri S., Patidar R., Hurd L., Chen L., Shern J.F., Liao H., Wen X., Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H., Picci P., Triche T.J., Horvai A.E., Miettinen M., Wei J.S., Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.
The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
PLoS Genet. 10:E1004475-E1004475(2014)

PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622
Tirode F., Surdez D., Ma X., Parker M., Le Deley M.C., Bahrami A., Zhang Z., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S., Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O., Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M., Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V., Michon J., Marec-Berard P., Gut I., Downing J., Dyer M., Zhang J., Delattre O.
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Cancer Discov. 4:1342-1353(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections Coriell; GM11654
DSMZ; ACC-516
Cell line databases/resources CCLE; TC71_BONE
Cosmic-CLP; 1240221
GDSC; 1240221
LINCS_LDP; LCL-1438
Ontologies BTO; BTO:0002604
CLO; CLO_0021329
EFO; EFO_0002865
Biological sample resources BioSample; SAMN03473241
Gene expression databases GEO; GSM510013
GEO; GSM887689
GEO; GSM888781
GEO; GSM1670525
GEO; GSM1676323
GEO; GSM1701656
Polymorphism and mutation databases Cosmic; 1078383
Cosmic; 1082507
Cosmic; 1112132
Cosmic; 1718433
Cosmic; 2228246
Cosmic; 2250474
Cosmic; 2294589